// Biotech and Pharma Therapeutics
Bayer aims Mirena at women’s health issue with no treatment
December 2, 2025 / Mirena / endometrial hyperplasia treatment / Bayer women’s health / NAEH clinical trial / non-cancerous uterine thickening
Bayer has launched a Phase 3 trial of its Mirena IUD to treat nonatypical endometrial hyperplasia (NAEH), a uterine condition without approved therapies that can progress to cancer. The trial will compare Mirena to oral progestins.
CDC’s ACIP set to discuss hepatitis B vaccines, childhood immunization schedule with new chairman
December 2, 2025 / ACIP vaccine policy / hepatitis B immunization / childhood vaccine schedule / CDC advisory committee / RFK Jr. vaccine oversight
CDC’s restructured ACIP will review hepatitis B vaccines, vaccine safety, and the childhood immunization schedule amid leadership changes and controversy. Upcoming deliberations could shift long‑standing vaccination practices despite strong evidence supporting existing pediatric vaccine recommendations.
C-suite leaders underprepared for AI deployment, says HFMA
December 3, 2025 / AI healthcare leadership / digital health strategy / HFMA executive survey / C-suite innovation trends / healthcare financial planning
Healthcare executives feel unprepared for AI integration and rising financial pressures, according to an HFMA report. Leaders emphasize the need for innovation, digital skills, and collaborative C-suite roles to transform care delivery and meet future demands.
Medtronic launches insulin delivery system with Abbott-made sensor
December 3, 2025 / Medtronic insulin pump / Abbott glucose sensor / MiniMed 780G system / diabetes technology integration / CGM insulin delivery
Medtronic has launched its MiniMed 780G insulin delivery system in the U.S., now paired with Abbott’s new 15-day Instinct glucose sensor. This marks a strategic shift allowing interoperability and expanded CGM options for diabetes management.
Top 5 VC Raises by Women-Founded Biopharmas
December 3, 2025 / women-founded biopharma / biotech venture capital / female biotech leadership / major VC fundraises / biopharma innovation trends
Female‑founded biopharma companies have raised $64B since 2008, with major VC rounds supporting innovations in oncology, neurology, RNA therapeutics and immunotherapy. Despite post‑pandemic funding declines, several women‑founded ventures remain pivotal drivers of biotech R&D advancement.
// 4th Industrial Revolution
Mount Sinai Deploys AI-Enhanced Fetal Ultrasounds, Achieves Near-Perfect Detection Rates for Congenital Heart Defects
December 2, 2025 / AI fetal ultrasound / congenital heart defects / prenatal diagnosis AI / Mount Sinai BrightHeart / obstetric imaging innovation
Mount Sinai implemented BrightHeart AI in fetal ultrasounds, achieving a 97% detection rate for congenital heart defects while improving clinician confidence and reducing interpretation time. This advancement enhances early prenatal diagnosis and standardizes care across diverse clinical settings.
Teletherapy Alone Will Not Solve The Mental Health Access Issue
December 2, 2025 / mental health devices / digital therapeutics reimbursement / behavioral health innovation / FDA-cleared mental health tools / teletherapy access limitations
Traditional mental health care models are insufficient for many patients. FDA-cleared digital therapeutics and biofeedback devices offer clinically validated alternatives, but limited insurance coverage hinders access. Integrating these tools with existing care models could enhance outcomes and engagement.
Seoul St. Mary’s Hospital introduces AI scribe and more briefs
December 2, 2025 / AI medical scribe / smart hospital Korea / EMR automation technology / voice-enabled documentation / AI clinical workflow
Seoul St. Mary’s Hospital is piloting CMC GenNote, an AI scribe developed with PuzzleAI to generate EMR entries from clinical conversations. This is part of a smart hospital initiative aimed at improving documentation efficiency across various departments.
New technique overcomes technological barrier in 3D brain imaging
December 2, 2025 / 3D brain imaging / high‑resolution X‑ray microscopy / neuronal connectomics / non‑destructive tissue imaging / neurodegenerative disease research
Swiss researchers achieved non-destructive 3D X‑ray imaging of brain tissue at unprecedented resolution, overcoming long-standing contrast limitations. The technique enables high‑resolution mapping of neuronal architecture and synaptic networks, opening new possibilities for studying brain connectivity and neurodegenerative diseases.
Philips Expands Light-Based Navigation and Introduces Full AI Spectral CT and Helium-Free 3.0T MRI
December 1, 2025 / AI spectral CT / helium-free MRI / 3D device navigation / diagnostic imaging innovation / radiation-free surgery
At RSNA 2025, Philips introduced LumiGuide for radiation-free 3D navigation, Verida AI-powered spectral CT for faster, high-resolution imaging, and BlueSeal Horizon—the world’s first helium-free 3.0T MRI—advancing sustainability, diagnostic precision, and workflow efficiency in medical imaging.
// Business & Markets
Curative Health Raises $150M, Reaches $1.275B Valuation to Disrupt Employer Health Insurance with AI and $0 Deductibles
DEcember 2, 2025 / AI health insurance / zero deductible care / employer health plans / preventive health model / Curative Cash Card
Curative Health raised $150M, reaching a $1.275B valuation for its AI-driven, $0-deductible employer health plan. The model improves outcomes with proactive care, reduces hospitalizations by 30%, and aims to expand nationwide with simplified, real-time payment systems.
Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline
December 1, 2025 / rare kidney disease / complement inhibitor ADX-097 / Akebia Q32 deal / phase 2 trial / alopecia areata therapy
Akebia Therapeutics acquired Q32 Bio’s complement inhibitor ADX-097 for $12M to anchor its rare kidney disease pipeline. A Phase 2 basket trial is planned for 2026, while Q32 reallocates resources to its alopecia areata antibody program.
Aidoc Partners with NVIDIA MONAI to Scale Open-Source Clinical AI
December 2, 2025 / Medicare drug pricing / semaglutide price cuts / CMS IRA savings / Ozempic Wegovy discount / prescription cost reduction
Aidoc has partnered with NVIDIA MONAI to integrate open-source imaging AI models into clinical workflows via its aiOS™ platform, solving deployment challenges. It also partnered with Quibim to enhance prostate cancer detection using AI-powered MRI analysis.
XRHealth acquires Innerworld to expand medical XR services
December 3, 2025 / XRHealth / immersive mental health / virtual reality therapy / cognitive behavioral immersion / XR behavioral care
XRHealth has acquired Innerworld to enhance its medical XR platform with immersive, community-based mental health care. This move supports a stepped care model for behavioral therapy, expanding access to virtual treatments for PTSD, OCD, addiction, and stress.
URMC and GE HealthCare Announce 7-Year Care Alliance to Deploy AI Imaging and Theranostics Center of Excellence
December 3, 2025 / AI imaging alliance / theranostics oncology care / URMC GE partnership / precision radiopharmaceuticals deployment / patient monitoring standardization
URMC and GE HealthCare have launched a 7-year alliance to deploy AI-driven imaging, theranostics, and system-wide patient monitoring. Key innovations include Aurora SPECT/CT, on-site radioisotope production, and standardized monitoring to advance precision oncology and improve care efficiency.
// Legal & Regulatory
FDA Seizes 7-OH Opioids to Protect American Consumers
December 2, 2025 / FDA opioid seizure / 7-OH supplement ban / illegal dietary ingredients / opioid abuse prevention / kratom derivative risks
The FDA seized 73,000 units of illegal 7-hydroxymitragynine (7-OH) products, a potent opioid not approved for medical use, due to safety concerns. These dietary supplements and foods posed significant abuse risks, especially to youth.
FDA details plan to scale back animal tests for some antibody drugs
December 2, 2025 / FDA antibody guidelines / animal testing alternatives / monoclonal antibody safety / organoid drug testing / drug development reform
The FDA issued draft guidance reducing the need for primate testing in early monoclonal antibody trials, encouraging human-relevant models and weight-of-evidence risk assessments to streamline development while maintaining safety.
Cleveland Diagnostics wins FDA nod for prostate cancer test
December 2, 2025 / prostate cancer test / IsoPSA FDA approval / PSA screening accuracy / biopsy risk assessment / blood-based diagnostics
The FDA approved Cleveland Diagnostics’ IsoPSA test, which analyzes protein structure—not just concentration—to better assess prostate cancer risk in men with elevated PSA levels, potentially reducing unnecessary biopsies and improving diagnostic accuracy.
FDA accelerated approvals under pressure
December 2, 2025 / FDA accelerated approval / surrogate clinical endpoints / expedited drug access / biomarker-based approval / oncology drug pathway
The FDA’s accelerated approval pathway speeds access to therapies for serious conditions by relying on surrogate endpoints, such as tumor response or biomarkers, that suggest likely clinical benefit before full efficacy data is available.
FDA issues draft guidance to reduce primate testing for certain antibodies
December 2, 2025 / FDA monoclonal antibody / animal testing reduction / drug safety alternatives / primate-free toxicology / new approach methodologies
The FDA issued draft guidance reducing nonhuman primate testing for certain monoclonal antibodies, encouraging alternative methods like shorter toxicity studies and prior antibody data, as part of a broader initiative to phase out animal testing and accelerate drug development.
// Research & Development
AbbVie reports Phase III study results of atogepant
December 2, 2025 / atogepant / migraine treatment / Phase III trial / CGRP antagonist / AbbVie study
AbbVie’s Phase III ECLIPSE study shows atogepant significantly improves acute migraine symptoms, achieving pain and symptom relief within two hours post-dose. The CGRP receptor antagonist demonstrated a consistent safety profile, supporting its potential for broader acute migraine treatment use.
Doctors are seeing more aggressive breast cancer in younger women than expected
December 1, 2025 / breast cancer / young women / early screening / aggressive tumors / cancer risk
New data shows a consistent rise in aggressive breast cancer cases among women under 40, prompting concerns that current screening guidelines may miss early detection and underscoring the need for earlier risk assessment in younger populations.
Roche Is Back in Alzheimer’s as Latest Antibody Clears Amyloid Plaques
December 2, 2025 / Alzheimer’s treatment / amyloid plaque removal / trontinemab antibody / Brainshuttle technology / Roche Alzheimer’s drug
Roche’s new antibody trontinemab cleared brain amyloid plaques in 92% of patients with early Alzheimer’s and showed a potential tau effect, with minimal brain swelling. Late-stage trials are underway, marking Roche’s renewed push in Alzheimer’s therapy development.
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An ‘Overreaction’?
December 2, 2025 / prostate cancer treatment / JANX007 response rate / PSA reduction data / cytokine release syndrome / Janux Therapeutics stock
Janux’s T-cell engager JANX007 showed a 30% response rate in heavily pretreated prostate cancer patients, with 73% achieving ≥50% PSA reduction. Despite stock volatility, safety improvements and PFS trends support continued development toward outpatient cancer therapy potential.
A routine shingles shot may offer powerful defense against dementia
December 3, 2025 / shingles vaccine dementia / dementia prevention vaccine / dementia risk reduction / shingles shot cognitive decline / vaccine therapeutic dementia
A shingles vaccine rollout in Wales revealed a significant reduction in dementia risk among vaccinated seniors, especially women. The effect persisted across analyses and may also offer therapeutic benefits for those already diagnosed with dementia.
// Politics
House endorses bill that would revive FDA’s rare pediatric review voucher program
December 2, 2025 / pediatric rare disease / FDA voucher program / drug development incentive / priority review voucher / rare disease treatment
The U.S. House has passed the Give Kids A Chance Act to reinstate the FDA’s rare pediatric disease priority review voucher (PRV) program, aiming to incentivize development of life-saving therapies for children with rare conditions.
Supreme Court hears oral arguments on crisis pregnancy centers
December 3, 2025 / hepatitis B vaccine / CDC vaccine advisory / ACIP transparency concerns / immunization policy review / vaccine expert exclusion
The CDC’s Advisory Committee on Immunization Practices (ACIP) is reviewing the hepatitis B vaccine without input from key CDC officials and external experts, raising concerns about transparency and deviation from standard advisory processes.
U.K. pledges to boost pharma payments, will avoid U.S. tariffs on drugs
December 1, 2025 / UK drug pricing / US pharma tariffs / international drug costs / pharmaceutical trade agreement / Trump drug policy
The U.K. agreed to raise pharmaceutical payments in a deal with the U.S., avoiding proposed drug tariffs. The move aligns with U.S. efforts to lower domestic drug prices by pushing other nations to pay more for medications.
AAM welcomes House approval of bill to boost generic competition
December 2, 2025 / generic drug approvals / FDA Q1 Q2 / affordable medicines access / patent expiry reform / generic competition legislation
The AAM supports House-passed Q1/Q2 legislation to speed generic drug approvals by clarifying inactive ingredient issues. The bill aims to reduce delays post-patent expiry, promoting faster access to affordable medications in the U.S. market.
Bipartisan bill intended to promote U.S. leadership in biotechnology
The bipartisan Biomanufacturing Excellence Act aims to boost U.S. leadership in biotechnology by strengthening domestic biopharmaceutical manufacturing, reducing reliance on foreign supply chains, expanding access to innovative medicines, and enhancing national security and public health.